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Key Points
•Unrelated-donor 7/8 BM
and UCB HCT led to
similar GRFS, CRFS, re-
lapse, and OS in children
with acute leukemia.
• The risk of grade III-IV
aGVHD was significantly
higher in the7/8BMgroup
than in the UCB group.
We report graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) (a composite
end point of survival without grade III-IV acute GVHD [aGVHD], systemic therapy–requiring
chronic GVHD [cGVHD], or relapse) and cGVHD-free relapse-free survival (CRFS) among
pediatric patients with acute leukemia (n 5 1613) who underwent transplantation with
1 antigen–mismatched (7/8) bone marrow (BM; n 5 172) or umbilical cord blood (UCB;
n 5 1441). Multivariate analysis was performed using Cox proportional hazards models. To
account for multiple testing, P, .01 for the donor/graft variable was considered statistically
signiﬁcant. Clinical characteristics were similar between UCB and 7/8 BM recipients,
because most had acute lymphoblastic leukemia (62%), 64% received total body
irradiation–based conditioning, and 60% received anti-thymocyte globulin or alemtuzumab.
Submitted 19 December 2018; accepted 7 March 2019. DOI 10.1182/
bloodadvances.2018030171.
The full-text version of this article contains a data supplement.
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Methotrexate-based GVHD prophylaxis wasmore commonwith 7/8 BM (79%) thanwith UCB
(15%), in which mycophenolate mofetil was commonly used. The univariate estimates of
GRFS and CRFS were 22% (95% conﬁdence interval [CI], 16-29) and 27% (95% CI, 20-34),
respectively, with 7/8 BM and 33% (95% CI, 31-36) and 38% (95% CI, 35-40), respectively, with
UCB (P, .001). In multivariate analysis, 7/8 BM vs UCB had similar GRFS (hazard ratio [HR],
1.12; 95% CI, 0.87-1.45; P 5 .39), CRFS (HR, 1.06; 95% CI, 0.82-1.38; P 5 .66), overall survival
(HR, 1.07; 95% CI, 0.80-1.44; P 5 .66), and relapse (HR, 1.44; 95% CI, 1.03-2.02; P 5 .03).
However, the 7/8 BM group had a signiﬁcantly higher risk for grade III-IV aGVHD (HR, 1.70;
95% CI, 1.16-2.48; P 5 .006) compared with the UCB group. UCB and 7/8 BM groups had
similar outcomes, as measured by GRFS and CRFS. However, given the higher risk for grade
III-IV aGVHD, UCB might be preferred for patients lacking matched donors.
Introduction
The probability of finding an HLA-matched donor for hematopoietic
cell transplantation (HCT) varies from 75% among whites with
European backgrounds to 16% among blacks of South or Central
American descent.1 In the absence of a matched related donor
(MRD) or unrelated donor (URD), options for alternative donor HCT
include umbilical cord blood transplantation (UCBT), haploidentical
HCT, or partially HLA–matched (7/8) bone marrow (BM) or 7/8
peripheral blood (PB) HCT from a URD. In pediatric patients, PB
grafts are rarely used because of the higher risks of chronic graft-
versus-host disease (cGVHD), treatment failure (relapse or death),
nonrelapse mortality (NRM), and overall mortality compared with BM.2
We compared the mortality and morbidity after pediatric alternative
donor HCT using data from the Center for International Blood and
Marrow Transplant Research (CIBMTR). We evaluated 2 novel
composite end points: GVHD-free relapse-free survival (GRFS) and
cGVHD-free relapse-free survival (CRFS). GRFS is defined as the
absence of grade III-IV acute GVHD (aGVHD), systemic therapy–
requiring cGVHD, relapse, or death. CRFS is defined as the
absence of systemic therapy–requiring cGVHD, relapse, or death.
We previously reported that BM grafts from MRDs led to superior
GRFS at 1 and 2 years compared with other graft/donor types.3,4
Here, we analyzed GRFS and CRFS among alternative (non-
matched) donor HCT for children with no available MRD or
matched URD.
Materials and methods
Objectives
The primary objective of the study was to compare GRFS and
CRFS among pediatric patients (age #18 years) with acute
leukemia who underwent an alternative donor HCT. Secondary
objectives were to describe the distribution and incidence of events
contributing to GRFS and CRFS.
Patient population
We included patients with acute myeloid leukemia (AML) or acute
lymphoblastic leukemia (ALL) in complete remission (CR) who
received a first alternative donor HCT (umbilical cord blood [UCB]
or 7/8 BM from an URD) with myeloablative conditioning between
2000 and 2014, as reported to the CIBMTR. Exclusion criteria were
the receipt of reduced-intensity conditioning, prior autologous or
allogeneic HCT, ex vivo T-cell depletion (TCD) or CD34 selected
graft, or UCB with ,4/6 HLA-matched units. 7/8 PB (n 5 48) and
haploidentical HCT (n 5 61) were excluded because of their small
numbers. Data on minimal residual disease to define the quality of
pre-HCT CR were not available. HLA matching for the UCB group
was determined using intermediate-resolution typing, and high-
resolution typing when available, for HLA-A and HLA-B loci
and high-resolution typing for HLA-DRB1 loci. Roughly half (47%;
n 5 680) had allele-level matching data available. The matching for
7/8 BM was done using high-resolution typing for HLA-A, HLA-B,
HLA-C, and HLA-DRB1 loci.
Definitions and statistical analysis
Disease risk was stratified as early or intermediate per the CIBMTR
standard criteria.5 Early disease was defined as AML/ALL in CR1,
and intermediate-risk disease was defined as AML/ALL beyond
CR1. Relapse was defined as the time from HCT to the clinical (not
molecular or minimal disease) recurrence of the underlying
leukemia. Death without relapse (NRM) was treated as a competing
risk. Leukemia-free survival (LFS) was defined as the time from HCT
to treatment failure (death or relapse). Overall survival (OS) was the
time from HCT to death from any cause. Patients with graft failure
(failure to engraft prior to subsequent HCT or death) were
censored, with the exception of NRM, which was not censored at
any point; if a patient died without relapse, they were classified as
NRM, regardless of subsequent HCT. aGVHD6 and cGVHD7,8
were diagnosed according to standard criteria, although National
Institutes of Health criteria9 for cGVHD were not prospectively used
in reports to the CIBMTR during most of the study period.
Multivariate analysis was performed using Cox proportional hazards
models. All clinical variables were tested for the proportional
hazards assumption. The graft/donor variable violated the propor-
tional hazards assumption for LFS and cGVHD. An optimal cut point
of 14 months was determined based on the maximum likelihood
method, and separate hazard ratios (HRs) were estimated before
and after 14 months. Other covariates that violated the proportional
hazards assumption were adjusted through stratification. A step-
wise modeling procedure selected factors using a threshold of 0.05
for entry and retention for model building. No 2-way interactions
between donor/graft and the adjusted clinical variables in the
models were detected at a 0.01 significance level. To account for
multiple testing, P, .01 for the donor/graft variable was considered
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statistically significant. Analysis was done using SAS software
version 9.4 (SAS Institute, Cary, NC).
Results
A total of 1613 patients was analyzed (UCB, n5 1441 and 7/8 BM,
n5 172; Table 1). The median age was 7 years (interquartile range,
3-11) in the UCB group and 10 years (interquartile range, 6-14)
in the 7/8 BM group. Overall, more than half (58%) were males. The
majority had ALL (62%), mostly in CR2; the rest had AML (38%),
with similar numbers in CR1 and later. A majority (64%) received
total body irradiation–based conditioning. In vivo TCD, with anti-
thymocyte globulin (ATG) or alemtuzumab, was used in ;60% of
patients. Methotrexate-based GVHD prophylaxis was used more
commonly in the 7/8 BM group (79%) than in the UCB group
(15%). Other characteristics were similar in both groups. Among
those who underwent UCBT, most (n 5 1240; 86%) received a
single UCB unit: 40% were 4/6 HLA matched, 44% were 5/6 HLA
matched, and 16% were 6/6 HLA matched to the recipient. In the
UCB group, the median precryopreservation total nucleated cell
(TNC) dose was 6 3 107 per kilogram (range, 1-28 3 107); few
patients (6%) had a TNC dose,33 107 per kilogram. In the 7/8 BM
group, an almost equal number of patients had an A-locus mismatch
(n 5 61; 36%) or a C-locus mismatch (n 5 63; 37%), followed by
B-locus mismatch (n5 30; 18%), whereas DRB1mismatch (n5 16;
9%) was infrequent. The median follow-up was 71 months (range,
3-198) in the UCB group and 96 months (range, 6-196) in the
7/8 BM group.
GRFS
In univariate analysis, UCB had significantly higher GRFS compared
with 7/8 BM (P , .001). One-year estimate of GRFS was 38%
(95% confidence interval [CI], 36-41) in the UCB group vs 29%
(95% CI, 22-36) in the 7/8 BM group; 2-year estimates were 33%
(95% CI, 31-36) and 22% (95% CI, 16-29), respectively. However,
in multivariate analysis stratified by GVHD prophylaxis (which was
tied to the graft source and the conditioning regimen), GRFS was
similar in both groups (Figure 1). Patients who received in vivo TCD
had significantly superior GRFS compared with those who did not.
Intermediate-risk disease status was associated with inferior GRFS
compared with early disease. Compared with non-Hispanic whites,
other racial and ethnic groups had worse GRFS (Table 2). When
analyzed by the number of mismatches in the UCB group, GRFS
was similar in groups that received HLA-matched UCB, 1 locus–
mismatched UCB (hazard ratio [HR], 1.02; 95% CI, 0.82-1.25;
P 5 .88), 2 loci–mismatched UCB (HR, 1.22; 95% CI, 0.99-1.51;
P 5 .07), and 7/8 BM (HR, 1.23; 95% CI, 0.9-1.68; P 5 .2). After
excluding patients who received double-unit UCB (dUCB), GRFS
was similar in the UCB and 7/8 BM groups (HR, 1.06; 95% CI,
0.93-1.20; P5 .39) (supplemental Table 1). After excluding patients
who received 6/6 HLA–matched UCB, GRFSwas similar in the UCB
and 7/8 BM groups (HR, 1.13; 95% CI, 0.86-1.48; P 5 .38)
(supplemental Table 2).
CRFS
The univariate estimates of CRFS after UCB at 1 year (43%; 95%
CI, 41-46) and 2 years (38%; 95% CI 35-40) were slightly higher
than those for 7/8 BM at 1 year (38%; 95% CI, 30-45) and 2 years
(27%; 95%CI, 20-34) (P5 .05). In multivariate analysis stratified by
GVHD prophylaxis, there was no difference in CRFS between
the donor groups (Figure 2). Patients with a Karnofsky or Lansky
Table 1. Baseline characteristics
UCB (n 5 1441) 7/8 BM (n 5 172)
Recipient age, median (interquartile range), y 7 (3-11) 10 (6-14)
Males 831 (58) 109 (63)
Female donor–to–male recipient 400 (28) 53 (31)
Disease status prior to HCT
ALL CR1 288 (20) 30 (17.5)
$CR2 606 (42) 78 (45)
AML CR1 281 (20) 30 (17.5)
$CR2 266 (18) 34 (20)
Time from diagnosis to HCT, median
(interquartile range), mo
14 (5-32) 18 (6-37)
ATG/alemtuzumab used 862 (60) 91 (53)
ATG* 851 (99) 63 (69)
Alemtuzumab 11 (1) 28 (31)
Conditioning regimen
Cy 1 TBI 6 other 920 (64) 122 (71)
Bu 1 Cy/Mel 6 other 353 (24) 25 (14)
Others† 168 (12) 25 (15)
GVHD prophylaxis
CNI 1 MMF 6 others (not Cy, MTX) 582 (40) 20 (11)
CNI 1 MTX 6 others (not Cy, MMF) 209 (15) 135 (79)
CNI 6 steroids 557 (39) 10 (6)
Others 6 CNI 72 (5) 7 (4)
Missing 21 (1) 0
Karnofsky/Lansky performance score‡
$90 1166 (81) 139 (81)
,90 225 (16) 18 (10)
Donor-recipient CMV serostatus
2/2 672 (47) 49 (29)
2/1 747 (52) 47 (27)
1/2 0 25 (15)
1/1 0 40 (23)
Missing 22 (1) 11 (6)
Recipient race, ethnicity
White, non-Hispanic 843 (59) 101 (59)
White, Hispanic 242 (17) 28 (16)
Nonwhite, non-Hispanic 245 (17) 32 (19)
Nonwhite, Hispanic 21 (1) 1 (,1)
Missing 90 (6) 10 (6)
Year of HCT
2000-2003 296 (20) 50 (29)
2004-2007 398 (28) 86 (50)
2008-2011 533 (37) 26 (15)
2012-2014 214 (15) 10 (6)
Follow-up, median (range), mo 71 (3-198) 96 (6-196)
Unless otherwise indicated, data are n (%).
Bu, busulfan; CMV, cytomegalovirus; CNI, calcineurin inhibitor; Cy, cyclophosphamide; Mel,
melphalan; MMF, mycophenolate mofetil; MTX, methotrexate; TBI, total body irradiation.
*One patient received ATG and alemtuzumab.
†Five patients had unknown conditioning regimens.
‡The Lansky scale was used for 99% of the recipients younger than 16 years, whereas
the Karnofsky scale was used for 94% of the recipients aged 16 to 17 years.
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performance score ,90 had significantly worse CRFS. Compared
with non-Hispanic whites, other racial and ethnic groups had inferior
CRFS (Table 2). When analyzed by the number of mismatches in
the UCB group, CRFS was similar in the groups that received
HLA-matched UCB, 1 locus–mismatched UCB (HR, 0.97; 95% CI,
0.78-1.21; P 5 .8), 2 loci–mismatched UCB (HR, 1.15; 95% CI,
0.93-1.44; P 5 .2), and 7/8 BM (HR, 1.11; 95% CI, 0.8-1.52;
P 5 .53). After excluding dUCB, CRFS was similar in the UCB
and 7/8 BM groups (HR, 1.03; 95% CI, 0.90-1.17; P 5 .66)
(supplemental Table 1). After excluding 6/6 HLA–matched UCB,
CRFS was similar in the UCB and 7/8 BM groups (HR, 1.06; 95% CI,
0.81-1.40; P 5 .68) (supplemental Table 2).
GVHD
The incidence of grade III-IV aGVHD at day 100 was 18% (95% CI,
16-21) in the UCB group and 29% (95% CI, 23-36) in the 7/8 BM
group (P , .001). In multivariate analysis stratified by age, the 7/8
BM group had a 70% higher risk of grade III-IV aGVHD compared
with the UCB group. Nonwhites had a significantly higher risk than
whites (Table 2). Similar findings were noted after excluding dUCB
(supplemental Table 1) and after excluding 6/6 HLA–matched
UCB (supplemental Table 2). Compared with HLA matched UCB,
the risk of aGVHD III-IV was slightly, but not significantly higher in
1 locus mismatched UCB (HR 1.94, 95% CI 1.15-3.26, P 5 .012),
but was significantly higher both in 2 loci mismatched UCB (HR 2.6,
95% CI 1.55-4.36, P 5 .0003) and in 7/8 BM (HR 3.6, 95% CI
1.98-6.57, P , .0001).
The estimates of cGVHD at 1- and 2 years were 22% (95% CI,
19-24) and 23% (95% CI, 20-25), respectively with UCB, but
significantly higher with 7/8 BM at 28% (95% CI, 22-35) and 34%
(95% CI, 27-41), respectively, P5 .004. In multivariate analysis, the
covariate of donor type violated the proportional hazards assump-
tion for cGVHD; therefore, a cutoff point of 14 months was used for
analysis. There was no difference in the risk of cGVHD with UCB
and 7/8 BM during the first 14 months post-HCT. However, beyond
14 months, 7/8 BM had a sixfold higher risk for cGVHD than UCB,
although there were only a few events (5 of 37 at risk) in the BM
group beyond 14 months. Similar findings were noted after
excluding dUCB (supplemental Table 1) and 6/6 HLA–matched
UCB (supplemental Table 2). Moreover, when analyzed by the
number of mismatches in the UCB group, the risk of cGVHD (before
or after 14 months) was similar in all UCB groups and the 7/8 BM
group (data not shown). The risk of cGVHDwas significantly higher in
those who did not receive in vivo TCD. Compared with non-Hispanic
whites, Hispanics and nonwhites had higher risks for cGVHD
(Table 2).
Relapse
Relapse risk was similar at 1 year (20% in both groups) or 2 years
(26% with UCB and 28% with 7/8 BM) (P 5 .22). In multivariate
analysis stratified by disease and age and adjusted for covariates,
including disease status, there was a trend toward a higher risk for
relapse in the 7/8 BM group (HR, 1.44; 95% CI, 1.03-2.02; P 5 .03)
(Table 2). Results remained unchanged after excluding dUCB
(supplemental Table 1) and 6/6 HLA–matched UCB (supplemental
Table 2). There was no difference in the risk of relapse among theHLA-
matched UCB, 1 locus–mismatched UCB (HR, 0.92; 95% CI, 0.69-
1.23; P5 .6), 2 loci–mismatched UCB (HR, 0.76; 95%CI, 0.56-1.04;
P5 .09), and 7/8 BM (HR, 1.24; 95% CI, 0.82-1.88; P5 .3) groups.
LFS/OS
The univariate estimates of LFS were similar at 1 year (60% in
both groups) and at 2 years (52% with UCB and 49% with 7/8 BM)
(P 5 .10). In multivariate analysis stratified by disease and GVHD
prophylaxis, UCB and 7/8 BM had similar LFS within the first
14 months of HCT (cutoff period chosen due to violation of
proportional hazard assumption). However, beyond 14 months, 7/8
BM had twofold inferior LFS compared with UCB. Again, this
should be interpreted with caution because of the relatively small
number of events (20 of 56 at risk) in the 7/8 BM group beyond
14 months. Exclusion of dUCB (supplemental Table 1) or 6/6
HLA–matched UCB (supplemental Table 2) yielded similar findings.
Moreover, when analyzed by the number of mismatches in the UCB
group, LFS was similar in all UCB groups and the 7/8 BM group,
before and after 14 months (data not shown). LFS was
significantly inferior in the CMV D2/R1 (seronegative donor/
seropositive recipient) group compared with the CMV2/2 group.
Factors associated with better LFS were Karnofsky or Lansky
performance score .90 and HCT performed between 2008 and
2011 (Table 2).
The univariate estimates of OS were similar in the UCB (66%;
95% CI, 64-68) and 7/8 BM (65%; 95% CI, 58-72) groups at
1 and 2 years (59% in both groups). Multivariate analysis
stratified by GVHD prophylaxis showed similar OS with 7/8 BM
and UCB (Table 2) and when restricted to single UCB only
(supplemental Table 2) or when restricted to mismatched-UCB
only (supplemental Table 2). The CMV D2/R1 group had a
significantly higher risk for mortality compared with the CMV2/2
group. Factors associated with superior OS were Karnofsky or
Lansky performance score .90, white race, and HCT performed
between 2008 and 2011 (Table 2). There was no difference in
OS between HLA-matched or -mismatched UCB and 7/8 BM
(data not shown).
Events contributing to GRFS and CRFS
In the UCB group, relapse (30%) and grade III-IV aGVHD (28%)
were the leading events accounting for GRFS, followed by cGVHD
(23%) and death (19%). In the 7/8 BM group, most events were
related to grade III-IV aGVHD (38%), followed by relapse and
cGVHD (24% each) and death (14%). With regard to the CRFS
events, cGVHD (35%) and relapse (36%) contributed almost equally
in the UCB group; in the 7/8 BM group, cGVHD was the most
common event (45%), followed by relapse (31%) and death (24%).
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Figure 1. Adjusted GRFS with UCBT and 7/8 BM HCT.
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In-patient hospital days and overall causes of death
The median number of days spent in the hospital within the first
100 days of HCT was similar in the UCB (46 days; interquartile
range, 34-67) and the 7/8 BM (44 days; interquartile range, 32-60)
groups.
Leukemia relapse was the principal cause of death in both groups
(43% each). GVHD contributed to 12% and 20% of deaths in the
UCB and 7/8 BM groups, respectively. Infection-related deaths
were more common in the UCB group (13%) than in the 7/8 BM
group (4%). Details about specific infections were not available.
More deaths due to organ failure, idiopathic pneumonia syndrome,
or acute respiratory distress syndrome occurred in the 7/8 BM
group (27%) than in the UCB group (15%). Two percent of deaths
in the UCB group were attributed to graft failure; none occurred
in the 7/8 BM group (supplemental Table 3).
Discussion
We observed that myeloablative UCB and 7/8 BM HCT in children
with acute leukemia led to similar survival without the morbidity
events, represented by GRFS and CRFS, and similar relapse and
OS, but with a 70% higher risk for grade III-IV aGVHD in the 7/8 BM
group. The risks of cGVHD and LFS were also similar in both
groups, at least up to 14 months, after which these outcomes
favored the UCB group, although definitive conclusions cannot be
made because of the limited numbers of late at-risk patients and
events in the 7/8 BM group. Similar findings were noted when
analyzed by the degree of mismatch (0, 1, or 2) in the UCB group,
because we did not find any differences in GRFS, CRFS, OS,
relapse, LFS, or cGVHD in the 7/8 BM group vs the UCB group,
regardless of the number of mismatches, although the risk for grade
III-IV aGVHDwas significantly higher in the 7/8 BM group than in the
HLA-matched UCB group. Because 2 randomized prospective trials
showed a higher risk for grade III-IV aGVHD10 and/or cGVHD10,11
with dUCB vs single-unit UCB transplantation, we performed
additional analyses after excluding dUCB and noted similar findings.
In addition to the donor/graft source, factors that had a significant
impact on HCT outcomes included the use of in vivo TCD, recipient
CMV serostatus, disease status, performance status, and the year
of HCT. The effects of in vivo TCD in UCBT have been studied
repeatedly with conflicting results reported,12-18 perhaps related to
the different types of ATG, as well as differing doses and timing. In
our study, in vivo TCD was associated with superior GRFS and a
reduced risk for cGVHD, without any impact on grade III-IV aGVHD,
CRFS, relapse, LFS, or OS. Also, although NRM was not 1 of the
studied end points, exploratory analysis revealed no impact of in vivo
TCD on NRM (data not shown). Because a vast majority of in vivo
TCD was achieved using ATG (99% in the UCB group and 69% in
the 7/8 BM group), subgroup analysis to investigate the impact of
ATG vs alemtuzumab could not be performed. In our study,
the risk of relapse was similar in patients with HLA-matched vs
HLA-mismatched UCB, which is consistent with the findings of
some studies19 and contrary to others.20,21 Although the precise
reason for this discrepancy is unclear, it might be related to different
study populations.
CMV donor/recipient serostatus also affected several HCT out-
comes. Because all UCB units areCMV seronegative, we focused on
seronegative donors, which constituted 94% of the entire study
population. Among these, CMV-seropositive recipients had notably
poorer LFS and OS compared with seronegative recipients. The
contribution of CMV reactivation to these outcomes is unclear, a
factor that is known to be associated with an increased risk for NRM
and poor OS.22-24
Transplantations performed between 2008 and 2011 were
associated with significantly higher LFS and OS and trended
toward superior GRFS compared with those performed before
2008. These data might be explained by the somewhat greater
number of patients with early disease (AML/CR1, 56% vs 46%;
ALL/CR1, 37% vs 24%-28%) and Karnofsky or Lansky score. 90
(84% vs 76%-79%) compared with previous years. Furthermore,
few patients received 7/8 BM grafts from 2008 onward (,5% vs
14%-18%), and fewer patients in the UCB group had a TNC dose
,33 107 per kilogram (,2% vs 7%-10%) compared with previous
years. These factors (ie, more patients undergoing UCB and with
higher cell dose, early-risk disease, and better performance status)
may have accounted for the findings noted. It is unclear why this
trend was not sustained in the latest study period (2012-2014);
however, it might be related to the relatively smaller number of
transplantations performed in this era than in the preceding years.
In addition, we noted significant racial and ethnic disparities in
outcomes. Whites, especially of non-Hispanic ethnicity, had a
remarkably lower risk for grade III-IV aGVHD or cGVHD and
superior GRFS, CRFS, LFS, and OS than other racial/ethnic
groups. As highlighted by other investigators, further research is
needed to decipher whether these differences are a surrogate
marker of confounders, such as their socioeconomic status, access
to health care, and education, or are directly related to differences in
biological factors, such as disparities in metabolism of chemother-
apy drugs or HLA matching.25,26
Previous studies showed comparable survival with UCB and HLA-
matched or -mismatched BM grafts, with some advantages and
no clear disadvantage of UCB.20,27 For instance, some studies
showed a lower risk for relapse with UCBT than with HLA-matched
BM HCT,20 and others showed lower aGVHD and cGVHD with
UCBT than with mismatched-BM HCT,27 with similar LFS and
OS.20,27 Our study, which is the largest and most recent of its kind,
adds to these data and provides a global perspective of outcomes,
as assessed by the novel composite end points (GRFS and CRFS),
in addition to the individual outcomes.
We acknowledge other limitations of our study besides its
retrospective nature. First, haploidentical HCTs were excluded
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Figure 2. Adjusted CRFS with UCBT and 7/8 BM HCT.
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because of the low number performed in children during this
time period. Most of the earlier haploidentical HCTs were performed
with CD341 selected or T-cell–depleted grafts,28-34 which were
associated with delayed immune reconstitution and high NRM
because of viral or fungal infections,32,33,35 high risk for relapse, and
poor LFS.30 These outcomes may improve with the use of novel
GVHD prophylaxis techniques, including posttransplantation
cyclophosphamide,36,37 selective depletion of ab T cells,38 or
T-cell–costimulation blockade.39 Next, the impact of the locus of
mismatch in the 7/8 BM group could not be assessed as a result of
the small subgroups. Moreover, the conditioning regimen of total
body irradiation, cyclophosphamide, and fludarabine is associated
with superior outcomes compared with other regimens in the UCBT
setting.40 The inclusion of a variety of non–total body irradiation,
cyclophosphamide, and fludarabine regimens may have diluted the
outcomes of UCBT in our study. Last, the data on measurable
residual disease pre- and post-HCT were unavailable.
We conclude that, in pediatric patients with acute leukemia,
myeloablative UCBT and 7/8 BM HCT led to similar GRFS,
CRFS, OS, and the relapse risk, although 7/8 BM group had
significantly higher risk of aGVHD III-IV, suggesting that
UCB may be preferred over 7/8 BM, especially if the UCB unit
is .4/6 HLA matched. Inclusion of novel GVHD prophylaxis
regimens may improve these outcomes for both approaches.
As experience develops in pediatric HCT, these outcomes will
need to be contrasted against haploidentical HCT to identify
preferred alternatives for patients without available matched
donors.
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